BMRN (BioMarin Pharmaceutical) 5-Year EBITDA Growth Rate: 63.80% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BMRN BioMarin Pharmaceutical Inc BMRN
85 GF Score
Price $64.41
GF Value $84.57
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical 5-Year EBITDA Growth Rate?

BioMarin Pharmaceutical BMRN -0.34% 85 5-Year EBITDA Growth Rate is 63.80% as of Jun. 2026. GuruFocus rates BMRN with a GF Score™ of 85/100 and a GF Value™ of $84.57 (Modestly Undervalued). The stock has 5 warning signs investors should review.

BioMarin Pharmaceutical's EBITDA per Share for the three months ended in Jun. 2026 was $1.14.

During the past 12 months, BioMarin Pharmaceutical's average EBITDA Per Share Growth Rate was -58.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 27.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 63.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of BioMarin Pharmaceutical was 133.80% per year. The lowest was -438.30% per year. And the median was 8.70% per year.

BioMarin Pharmaceutical  (NAS:BMRN) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

BioMarin Pharmaceutical 5-Year EBITDA Growth Rate Related Terms

BMRN vs MDGL, CORT, ARWR: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioMarin Pharmaceutical 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate falls into.


BMRN
85GF Score
BioMarin Pharmaceutical Inc BMRN
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 63.80% mean?
BioMarin Pharmaceutical (BMRN) has a 5-Year EBITDA Growth Rate of 63.80% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for BioMarin Pharmaceutical and its competitors.
Is BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate too high?
BioMarin Pharmaceutical's current 5-Year EBITDA Growth Rate is 63.80%. Overall, BioMarin Pharmaceutical has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate compare to MDGL and CORT?
BioMarin Pharmaceutical's 5-Year EBITDA Growth Rate of 63.80% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current 5-Year EBITDA Growth Rate is 63.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (BMRN) is currently considered Modestly Undervalued. The stock's GF Value™ is $84.57, compared to a current price of $64.41 — trading 23.8% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 63.80%. BioMarin Pharmaceutical's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For BioMarin Pharmaceutical (BMRN), the current 5-Year EBITDA Growth Rate is 63.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMarin Pharmaceutical (BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of $64.41 is trading 23.8% below its estimated GF Value™ of $84.57. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for BMRN:

  • 5-Year EBITDA Growth Rate: 63.80%
  • GF Value™: $84.57 vs. price of $64.41 (23.8% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
85GF Score

Get the complete analysis for BMRN

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$64.41
Price
$84.57
GF Value